How to choose a pharmaceutical lead generation provider — without getting burned.

Here’s a pattern we see all the time with pharma and life-sciences companies.

Excellent science. A clean validation record. A line that runs to spec, or a service that passes audits without a sweat. A technical team that knows the chemistry, the modality, and the compliance regime cold.

Empty sales pipeline.

The business runs on referrals, repeat accounts, and the occasional RFP that lands through industry connections. It works — until it doesn’t. Until a key account moves a program to a competing CDMO. Until a formulary decision goes the other way. Until leadership realizes the company hasn’t opened a net-new account in two quarters.

Great pharma and life-sciences companies are built by scientists and operators who are exceptional at making and validating product, not by salespeople who are exceptional at finding new buyers. So the question becomes: do you build an in-house SDR team, or do you bring in a specialist?

To choose a pharmaceutical lead generation provider that delivers real pipeline: verify their SDRs understand GxP, clinical phases, and formulary dynamics, inspect their messaging for therapeutic and value-chain specificity (not “healthcare”-generic templates), confirm they map your position in the value chain before the first dial, and require pipeline-based success metrics — not meeting volume guarantees.

Most pharma and life-sciences companies with fewer than 30 sales reps are better off outsourcing prospecting to a specialist. Here’s the math and the reasoning.

When in-house makes sense:

• You’re an enterprise pharma or life-sciences company with a 50+ person commercial organization that already has a defined SDR function
• Your therapeutic focus and ICP are locked in, your outreach process is working, and you need to scale what’s already proven
• Your sales motion requires deep scientific and account knowledge that only comes from institutional memory

When outsourcing makes sense (most pharma and life-sciences companies):

• You’re building an SDR function from scratch and don’t have a playbook for technical, regulated selling
• You’re testing a new therapeutic area, modality, or value-chain segment before committing headcount
• Pipeline is inconsistent and the root cause is top-of-funnel volume and targeting, not close rate
• Your AEs and sales engineers are spending time on prospecting instead of running technical evaluations and closing

The cost comparison:

An in-house SDR selling into pharma needs to understand GxP and GMP expectations, clinical phases, formulary and GPO dynamics, CDMO/CRO models, and how to have a credible conversation with a principal scientist or QA director. That knowledge doesn’t come from an onboarding doc. Months 1 through 4 are usually at 40 to 50% capacity. You’re paying for the whole thing.

Then there’s turnover. The average SDR tenure in B2B is 14 to 16 months. If yours leaves at month 10, you restart from zero — same cost, same ramp, none of the life-sciences market knowledge they built.

A qualified pharmaceutical lead gen provider doesn’t just book meetings. They understand the pharma buying cycle, the full committee of scientific and commercial stakeholders, and when an account is actually in an active sourcing window.

What they should handle:

• Building hyper-targeted lists by therapeutic area, value-chain position, modality, GxP and accreditation status, and revenue band — not just “pharma companies” filtered by headcount
• Monitoring trigger events: clinical milestone announcements, capacity expansions, supplier-qualification cycles, leadership changes in QA or commercial, new facility or line investments
• Running multi-channel outreach (email + phone + LinkedIn) with therapeutic- and value-chain-specific messaging — not “healthcare”-generic templates a medical-device rep could send unchanged
• Tracking intent signals across clinical, regulatory, and industry sources relevant to your segment
• Mapping the full buying committee — principal scientists, QA and regulatory directors, procurement, finance, formulary or GPO contacts — and sequencing outreach accordingly
• Responding to inbound RFI and RFP inquiries within the 5-minute window that converts at 21x the rate of 30-minute responses

What they should NOT be doing:

• Sending generic “we provide pharma solutions” cold emails to unqualified lists
• Targeting life-sciences buyers without segmenting by value-chain position, therapeutic area, or modality
• Booking meetings with companies that aren’t a fit before qualifying for scientific fit, compliance posture, and an active sourcing window
• Treating all leads the same regardless of whether they’re in active evaluation or just casually researching

92% of B2B buyers have a vendor already in mind before formal evaluation begins. A provider who can’t explain how to build awareness before the RFP window opens doesn’t understand your market.

For a deeper look at the specific strategies a pharma provider should be running on your behalf, see Lead Generation Strategies for Pharma Companies.

The questions below separate providers who understand the pharma selling motion from generalist agencies that will paste your logo into their standard “healthcare” template.

1. “Do your SDRs understand GxP, GMP, formulary and GPO dynamics, clinical phases, and CDMO/CRO models?”
The right answer demonstrates real fluency: they can explain what a Phase II readout means for a sponsor’s sourcing timeline, how a GPO contract shapes a hospital-pharmacy buy, or why a CDMO sells capacity and quality systems rather than a therapeutic story. Wrong answer: “Our reps are trained on healthcare.” That’s a category, not fluency.

2. “How do you map our position in the value chain — and the prospect’s?”
The right answer shows they classify every prospect as manufacturer, CDMO, CRO, distributor, or provider before the first dial, and tune messaging to it. Wrong answer: anything that suggests they’d pitch a contract manufacturer the same way they’d pitch a wholesaler.

3. “How do you stay compliant with vendor-qualification, NDA, and access rules?”
The right answer includes documented, consent-aware outreach, briefing SDRs on what they can and can’t say about indications, off-label topics, and pricing, and logging every touch for an auditable trail. Wrong answer: “We just send the emails.” Cold-blasting a regulated list is a compliance flag waiting to happen.

4. “How do you define and qualify a lead?”
The right answer is a three-point standard — verified pain, decision authority, and an active timeline — with all three required before a meeting is booked. Wrong answer: “We hit your meeting target.” A meeting with someone who can’t buy, on no timeline, isn’t pipeline.

5. “Can you segment by therapeutic area, modality, and value-chain segment?”
The right answer layers therapeutic area, modality (small molecule, biologic, cell and gene), value-chain position, GxP and accreditation status, revenue band, and geography. Wrong answer: “We pull pharma companies from a list vendor.”

6. “How do you handle 9 to 18 month, multi-stakeholder sales cycles?”
The right answer sequences engagement by stakeholder — scientific and technical buyers first, QA, regulatory, procurement, and finance later — and keeps SDRs involved through nurture so the handoff to your AE doesn’t reset the relationship. Wrong answer: “We book the meeting and you take it from there.”

7. “What does reporting and CRM integration look like?”
The right answer demonstrates pipeline-to-close reporting, cost per qualified opportunity, and native integration with your CRM so every touch and outcome is auditable. Wrong answer: a weekly spreadsheet of meeting counts with no pipeline view.

Most pharma lead gen failures come from the same handful of mistakes. These are the warning signs.

1. They pitch generic “healthcare” with no pharma nuance. If a provider treats a branded manufacturer, a CDMO, and a hospital-pharmacy buyer as one undifferentiated “healthcare” audience, they don’t understand your market. Ask them to explain how a CDMO buys differently from a wholesaler. A blank or hand-wavy answer tells you everything.

2. They guarantee a fixed number of meetings. Meeting volume without qualification criteria is the most common lead gen red flag. A provider promising 20 meetings per month will book 20 — with whoever they can reach. If they can’t define what “qualified” means in pharma (right value-chain position, scientific fit, decision authority, active timeline), the meetings will be with people who can’t buy.

3. They lean on a replacement-guarantee gimmick. “We’ll replace any meeting that doesn’t qualify” sounds reassuring and means nothing — it just resets the clock with more unqualified meetings. A real partner defines qualification up front and is measured on pipeline, not on a refund policy for their own misses. Treat the guarantee as a tell that they expect to miss.

4. They have no compliance or GxP awareness. If a provider can’t describe how they keep outreach consent-aware, how they brief SDRs on off-label and pricing boundaries, or how touches get logged for an audit trail, they’re a compliance incident waiting to happen. Ask specifically how they’d run outreach inside your vendor-qualification and NDA rules.

5. Their reps are junior script-readers. Pharma buyers are PharmDs, principal scientists, and QA directors who screen out generic outreach in seconds. If the provider’s SDRs can’t hold a credible conversation about your modality or compliance regime without a script, your prospects will notice — and disengage.

6. They don’t map the value chain. If a provider pitches a contract manufacturer like a wholesaler, or a GPO like a single site, they haven’t done the one piece of homework that matters most in pharma. Ask them to walk through how they’d classify and message three different prospects. If it’s the same message three times, move on.

Track these metrics at 30, 60, and 90 days. If the numbers aren’t moving by day 90, the problem is either ICP definition, messaging quality, or provider capability — and the earlier you diagnose which one, the less budget you burn.

At 30 days: Review messaging quality and list targeting. If contact rates are below 10%, the list is wrong. Make one change at a time so you know what moved the needle.

At 60 days: First pipeline entries should be visible. If you’ve had qualified first meetings but zero pipeline created, check whether qualification criteria align between your team and the provider’s definition of “qualified.”

At 90 days: Full evaluation point. If pipeline is moving and meetings are converting at target rates, continue and consider expanding scope. If it’s flat, ask: “Here’s what we expected, here’s what we have. What’s your diagnosis and your solution?” A provider with no specific answer at 90 days is not your long-term partner.

Tip: The metric to watch hardest early: meeting show rate. If prospects are booking and then ghosting, the provider is booking meetings with people who were never really interested. That tells you qualification is failing before the meeting even happens.

The best lead gen provider in the world will underperform if they don’t have the right inputs from you in week one.

What to provide at kickoff:

• Your ICP: Specific therapeutic areas or value-chain segments, modality, GxP and accreditation status, revenue band, geographic coverage, and procurement maturity
• Your best current clients: Five to ten examples so the provider can reverse-engineer what a great fit looks like — the segment, the modality, the buying process
• Your proof points: Validation records, audit outcomes, capacity figures, or clinical results from specific programs. Numbers, not claims.
• Your case studies: At least one per target segment. The provider will use these in outbound sequences and in RFP responses.
• Your buying committee map: Who you typically engage — scientific, QA, regulatory, procurement, finance — in what order, and what each person’s core concern is
• Your compliance rules: Vendor-qualification expectations, NDA requirements, GxP boundaries, and what SDRs can and can’t say about indications and pricing

What you should not expect the provider to invent:

• Your value proposition — they can sharpen the messaging, not create the substance
• Your case studies — if you don’t have published case studies from your target segments, build them before the engagement starts
• Your pricing and contract structure — they’ll need to reference it in conversations; ambiguity here kills qualified meetings
• Your compliance posture — the QA and regulatory gatekeepers will ask about GxP, serialization, and quality systems; the provider needs real answers

The most common reason pharma lead gen programs underperform isn’t provider quality — it’s insufficient inputs at kickoff. A provider can’t build compelling outreach around generic service descriptions. Give them specifics.

Most pharmaceutical lead generation engagements run $40,000 to $55,000 over six months for a fully managed program. That includes list building, multi-channel outreach execution, intent monitoring, buying committee mapping, and reporting.

The number that’s easy to undercount in the in-house model: the cost of the ramp period. An SDR at 40 to 50% capacity for three to four months while you’re paying full salary and tools doesn’t show up as a line item — but it shows up in the pipeline you didn’t build during that window.

With an outsourced provider, execution starts in week one. The ramp is already done. The life-sciences market knowledge is already in place.

The real cost of in-house isn’t salary — it’s the three to four months of lost pipeline opportunity while the SDR learns the difference between selling commodity supplies and selling into a validation-bound, committee-driven pharma buy. Those are not the same thing.

Stop evaluating providers on their sales pitch. Start evaluating them on the 7 questions and 6 red flags above.

Pull the last provider’s results. How many “leads” turned into pipeline? How many meetings actually happened? How many of those meetings involved a buyer who could authorize a contract?

If the answers are uncomfortable, the problem wasn’t budget. It was the selection criteria.

What’s your 90-day pipeline target, and does your current prospecting system have a realistic path to hit it?